Wire · opportunities
Henlius Accelerates the New Landscape of Breast Cancer Treatment as HANQUYOU Marks ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
Henlius' HANQUYOU trastuzumab biosimilar marks six years since Chinese and European approvals, becoming a global benchmark for China-developed monoclonal antibodies in HER2-positive breast cancer treatment. The drug is approved in over 50 countries, includes dual dosage strengths for better dosing and patient safety, and has been included in several national essential medicines lists and insurance systems, enhancing accessibility.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can expand your breast cancer product line by adopting Henlius’ tailored dual-dosage trastuzumab design to reduce wastage and improve patient safety. Access to national essential medicine lists and insurance coverage now lowers market entry barriers and widens patient reach.
◆ Coverage
1 source · 12 Aug 2026
◆ Related on Wire
◆ Topics